Trial Profile
Phase I study of Gleevec (imatinib mesylate, formerly known as STI1571) and gemcitabine in patient with refractory solid-tumor malignancy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2006
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions
- 19 Jan 2006 New trial record.